Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

NCT02214407 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

170

Enrollment

OTHER

Sponsor class

Conditions

MDS

Interventions

DRUG: Decitabine
DRUG: HYDROXYUREA

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]